TEZEMLIMOGENE DAXADENOREPVEC
UNII B7N7BR6M4A

Substance Identification & Data

This profile provides standardized clinical and technical data for Tezemlimogene Daxadenorepvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) B7N7BR6M4A.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2642046-11-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
B7N7BR6M4A
CAS Registry Number
2642046-11-3
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TEZEMLIMOGENE DAXADENOREPVEC
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C160192
National Cancer Institute reference terminology for clinical and research data.
INN ID
12282
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tezemlimogene Daxadenorepvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TEZEMLIMOGENE DAXADENOREPVEC

Common Names & Synonyms

DNA (RECOMBINANT HUMAN ADENOVIRUS 5 .DELTA.E1A.DELTA.E3 VECTOR DNX-2440 SIMIAN CYTOMEGALOVIRUS IMMEDIATE-EARLY PROMOTER-ENHANCER PLUS HUMAN OX40 LIGAND GENE PLUS BOS TAURUS GROWTH HORMONE POLYADENYLATION SIGNAL PLUS VIRAL FIBER PROTEIN RGD MOTIF INSERTION MUTEIN-SPECIFYING)
RECOMBINANT CONDITIONALLY REPLICATION-COMPETENT ONCOLYTIC ADENOVIRUS TYPE 5 (AD5) ENCODING HUMAN IMMUNE MODULATORY PROTEIN OX40 LIGAND (OX40L, CD252, TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 4) UNDER CONTROL OF THE CYTOMEGALOVIRUS (CMV) IMMEDIATE-EARLY PROMOTER-ENHANCER AND TERMINATED WITH THE BOVINE GROWTH HORMONE (BGH) POLYADENYLATION SEQUENCE. THE OX40L SEQUENCE ALONG WITH THE CMV IMMEDIATE-EARLY PROMOTER AND BGH POLYADENYLATION SIGNAL IS INSERTED INTO THE AD5 E3 REGION, DISPLACING APPROXIMATELY 2.69 KB OF THE E3 REGION. GENETIC MODIFICATION ALSO INCLUDES A 24 BP DELETION IN THE E1A GENE AND A 27 BP INSERTION INTO THE FIBER GENE WHICH INTRODUCES AN RGD (ARG-GLY-ASP) MOTIF
TEZEMLIMOGENE DAXADENOREPVEC [INN]

Technical Codes

DNX-2440

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus